Noyes Center For Kidney Disease And Dialysis is a medicare approved dialysis facility center in Geneseo, New York and it has 16 dialysis stations. It is located in Livingston county at 4616 Millennium Drive, Geneseo, NY, 14454. You can reach out to the office of Noyes Center For Kidney Disease And Dialysis at (585) 991-5015. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Noyes Center For Kidney Disease And Dialysis has the following ownership type - Non-Profit. It was first certified by medicare in June, 2008. The medicare id for this facility is 333553 and it accepts patients under medicare ESRD program.
| Name | Noyes Center For Kidney Disease And Dialysis |
|---|---|
| Location | 4616 Millennium Drive, Geneseo, New York |
| No. of Dialysis Stations | 16 |
| Medicare ID | 333553 |
| Managed By | Independent |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 4616 Millennium Drive, Geneseo, New York, 14454 | |
| (585) 991-5015 | |
News Archive
BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two models, for dual- and single-chamber pacing therapy, and offers individualized patient therapy, easy handling and flexibility in every detail. Reocor enriches BIOTRONIK's portfolio of high quality cardiovascular devices and sets a new standard of quality for external pacing therapy.
A new study appearing in the Journal of Bone and Joint Surgery found that administering tranexamic acid (TXA) both intravenously (IV) and injected at the surgical site (intra-articular administration, or IA) reduced blood loss by 37 percent, compared to IV alone, following total knee replacement (TKR).
UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
A series examining how the U.S. public health front lines have been left understaffed and ill-prepared to save us from the coronavirus pandemic.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 6 days ago
| NPI Number | 1912175621 |
| Organization Name | Noyes Center For Kidney Disease And Dialysis |
| Doing Business As | Nicholas H. Noyes Memorial Hospital |
| Address | 4616 Milllenium Dr Geneseo, New York, 14454 |
| Phone Number | (585) 991-5105 |
News Archive
BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two models, for dual- and single-chamber pacing therapy, and offers individualized patient therapy, easy handling and flexibility in every detail. Reocor enriches BIOTRONIK's portfolio of high quality cardiovascular devices and sets a new standard of quality for external pacing therapy.
A new study appearing in the Journal of Bone and Joint Surgery found that administering tranexamic acid (TXA) both intravenously (IV) and injected at the surgical site (intra-articular administration, or IA) reduced blood loss by 37 percent, compared to IV alone, following total knee replacement (TKR).
UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
A series examining how the U.S. public health front lines have been left understaffed and ill-prepared to save us from the coronavirus pandemic.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 44 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 11 |
News Archive
BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two models, for dual- and single-chamber pacing therapy, and offers individualized patient therapy, easy handling and flexibility in every detail. Reocor enriches BIOTRONIK's portfolio of high quality cardiovascular devices and sets a new standard of quality for external pacing therapy.
A new study appearing in the Journal of Bone and Joint Surgery found that administering tranexamic acid (TXA) both intravenously (IV) and injected at the surgical site (intra-articular administration, or IA) reduced blood loss by 37 percent, compared to IV alone, following total knee replacement (TKR).
UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
A series examining how the U.S. public health front lines have been left understaffed and ill-prepared to save us from the coronavirus pandemic.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 85 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 737 |
| Percentage of adult patients getting regular hemodialysis at the center | 96 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two models, for dual- and single-chamber pacing therapy, and offers individualized patient therapy, easy handling and flexibility in every detail. Reocor enriches BIOTRONIK's portfolio of high quality cardiovascular devices and sets a new standard of quality for external pacing therapy.
A new study appearing in the Journal of Bone and Joint Surgery found that administering tranexamic acid (TXA) both intravenously (IV) and injected at the surgical site (intra-articular administration, or IA) reduced blood loss by 37 percent, compared to IV alone, following total knee replacement (TKR).
UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
A series examining how the U.S. public health front lines have been left understaffed and ill-prepared to save us from the coronavirus pandemic.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 6 days ago
| Adult patients getting regular peritoneal dialysis at the center | 9 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 50 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two models, for dual- and single-chamber pacing therapy, and offers individualized patient therapy, easy handling and flexibility in every detail. Reocor enriches BIOTRONIK's portfolio of high quality cardiovascular devices and sets a new standard of quality for external pacing therapy.
A new study appearing in the Journal of Bone and Joint Surgery found that administering tranexamic acid (TXA) both intravenously (IV) and injected at the surgical site (intra-articular administration, or IA) reduced blood loss by 37 percent, compared to IV alone, following total knee replacement (TKR).
UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
A series examining how the U.S. public health front lines have been left understaffed and ill-prepared to save us from the coronavirus pandemic.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Noyes Center For Kidney Disease And Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 91 |
| Hypercalcemia patient months | 799 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 101 |
| Patients with Serumphosphor less than 3.5 mg/dL | 9 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 28 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 19 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 25 |
| Patients with Serumphosphor greater than 7 mg/dL | 19 |
News Archive
BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two models, for dual- and single-chamber pacing therapy, and offers individualized patient therapy, easy handling and flexibility in every detail. Reocor enriches BIOTRONIK's portfolio of high quality cardiovascular devices and sets a new standard of quality for external pacing therapy.
A new study appearing in the Journal of Bone and Joint Surgery found that administering tranexamic acid (TXA) both intravenously (IV) and injected at the surgical site (intra-articular administration, or IA) reduced blood loss by 37 percent, compared to IV alone, following total knee replacement (TKR).
UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
A series examining how the U.S. public health front lines have been left understaffed and ill-prepared to save us from the coronavirus pandemic.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 69 |
| Patient months included in arterial venous fistula and catheter summaries | 544 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 79 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 16 |
News Archive
BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two models, for dual- and single-chamber pacing therapy, and offers individualized patient therapy, easy handling and flexibility in every detail. Reocor enriches BIOTRONIK's portfolio of high quality cardiovascular devices and sets a new standard of quality for external pacing therapy.
A new study appearing in the Journal of Bone and Joint Surgery found that administering tranexamic acid (TXA) both intravenously (IV) and injected at the surgical site (intra-articular administration, or IA) reduced blood loss by 37 percent, compared to IV alone, following total knee replacement (TKR).
UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
A series examining how the U.S. public health front lines have been left understaffed and ill-prepared to save us from the coronavirus pandemic.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 73 |
| Hospitalization Rate in facility | 185.6 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 320 |
| Hospitalization Rate: Lower Confidence Limit | 110.9 |
News Archive
BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two models, for dual- and single-chamber pacing therapy, and offers individualized patient therapy, easy handling and flexibility in every detail. Reocor enriches BIOTRONIK's portfolio of high quality cardiovascular devices and sets a new standard of quality for external pacing therapy.
A new study appearing in the Journal of Bone and Joint Surgery found that administering tranexamic acid (TXA) both intravenously (IV) and injected at the surgical site (intra-articular administration, or IA) reduced blood loss by 37 percent, compared to IV alone, following total knee replacement (TKR).
UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
A series examining how the U.S. public health front lines have been left understaffed and ill-prepared to save us from the coronavirus pandemic.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 6 days ago
The rate of readmission show you whether patients who were being treated regularly at Noyes Center For Kidney Disease And Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 19.3 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 29.1 |
| Readmission Rate: Lower Confidence Limit | 11.5 |
News Archive
BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two models, for dual- and single-chamber pacing therapy, and offers individualized patient therapy, easy handling and flexibility in every detail. Reocor enriches BIOTRONIK's portfolio of high quality cardiovascular devices and sets a new standard of quality for external pacing therapy.
A new study appearing in the Journal of Bone and Joint Surgery found that administering tranexamic acid (TXA) both intravenously (IV) and injected at the surgical site (intra-articular administration, or IA) reduced blood loss by 37 percent, compared to IV alone, following total knee replacement (TKR).
UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
A series examining how the U.S. public health front lines have been left understaffed and ill-prepared to save us from the coronavirus pandemic.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 6 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Noyes Center For Kidney Disease And Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.56 (As Expected) |
| SIR: Upper Confidence Limit | 2.85 |
| SIR: Lower Confidence Limit | .76 |
News Archive
BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two models, for dual- and single-chamber pacing therapy, and offers individualized patient therapy, easy handling and flexibility in every detail. Reocor enriches BIOTRONIK's portfolio of high quality cardiovascular devices and sets a new standard of quality for external pacing therapy.
A new study appearing in the Journal of Bone and Joint Surgery found that administering tranexamic acid (TXA) both intravenously (IV) and injected at the surgical site (intra-articular administration, or IA) reduced blood loss by 37 percent, compared to IV alone, following total knee replacement (TKR).
UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
A series examining how the U.S. public health front lines have been left understaffed and ill-prepared to save us from the coronavirus pandemic.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 6 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Noyes Center For Kidney Disease And Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 66 |
| Transfusion Rate in facility | 28.5 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 82.6 |
| Transfusion Rate: Lower Confidence Limit | 11.2 |
News Archive
BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two models, for dual- and single-chamber pacing therapy, and offers individualized patient therapy, easy handling and flexibility in every detail. Reocor enriches BIOTRONIK's portfolio of high quality cardiovascular devices and sets a new standard of quality for external pacing therapy.
A new study appearing in the Journal of Bone and Joint Surgery found that administering tranexamic acid (TXA) both intravenously (IV) and injected at the surgical site (intra-articular administration, or IA) reduced blood loss by 37 percent, compared to IV alone, following total knee replacement (TKR).
UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
A series examining how the U.S. public health front lines have been left understaffed and ill-prepared to save us from the coronavirus pandemic.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 6 days ago
The rate of mortality show you whether patients who were being treated regularly at Noyes Center For Kidney Disease And Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 335 |
| Mortality Rate in facility | 16 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 20.7 |
| Mortality Rate: Lower Confidence Limit | 12.1 |
News Archive
BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two models, for dual- and single-chamber pacing therapy, and offers individualized patient therapy, easy handling and flexibility in every detail. Reocor enriches BIOTRONIK's portfolio of high quality cardiovascular devices and sets a new standard of quality for external pacing therapy.
A new study appearing in the Journal of Bone and Joint Surgery found that administering tranexamic acid (TXA) both intravenously (IV) and injected at the surgical site (intra-articular administration, or IA) reduced blood loss by 37 percent, compared to IV alone, following total knee replacement (TKR).
UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
A series examining how the U.S. public health front lines have been left understaffed and ill-prepared to save us from the coronavirus pandemic.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 6 days ago
Noyes Center For Kidney Disease And Dialysis Location: 4616 Millennium Drive, Geneseo, New York, 14454 Phone: (585) 991-5015 |
News Archive
BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two models, for dual- and single-chamber pacing therapy, and offers individualized patient therapy, easy handling and flexibility in every detail. Reocor enriches BIOTRONIK's portfolio of high quality cardiovascular devices and sets a new standard of quality for external pacing therapy.
A new study appearing in the Journal of Bone and Joint Surgery found that administering tranexamic acid (TXA) both intravenously (IV) and injected at the surgical site (intra-articular administration, or IA) reduced blood loss by 37 percent, compared to IV alone, following total knee replacement (TKR).
UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
A series examining how the U.S. public health front lines have been left understaffed and ill-prepared to save us from the coronavirus pandemic.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 6 days ago